Informing relatives of heart or lung transplantation patients
The results of this qualitative study showed a gap between the information and support that relatives to newly listed heart or lung transplant patients need and receive. The professional teams and society in general must better understand the experiences, resources and challenges that the relatives face. More about this study Topics: Cardiovascular Nursing
We read with great interest the review by Yanagawa et al, entitled Surgery for tumors of the heart,1 where the authors thoroughly review cardiac tumors classification, diagnosis sequence as well as the suggested method of treatment for the different kinds of tumors. The authors address sarcoma's as one of the rare malignant tumors and suggest a two-step surgical approach to sarcoma that involve the heart and lung.
Chronic lung allograft dysfunction or CLAD, encompasses a variety of phenotypes including both obstructive and restrictive phenotypes as detected by pulmonary function testing (PFTs), and has advanced the understanding of current clinical guidelines1-5. From the initial classification of chronic lung allograft rejection based primarily on pulmonary function testing, clinical guidelines now encompass CLAD phenotypes, presumed causes, characteristic imaging findings, and refinement of histopathological grades.
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
By ANISH KOKA MD The message comes in over the office slack line at 1:05 pm. There are four patients in rooms, one new, 3 patients in the waiting room. Really, not an ideal time to deal with this particular message. “Kathy the home care nurse for Mrs. C called and said her weight yesterday was 185, today it is 194, she has +4 pitting edema, heart rate 120, BP 140/70 standing, 120/64 sitting” I know Mrs. C well. She has severe COPD from smoking for 45 of the last 55 years. Every breath looks like an effort because it is. The worst part of it all is that Mrs. C just returned home from the hospital just days...
Left Ventricular Assist Device (LVAD) support is a well established therapy for treatment of adult patients with end-stage heart failure (ESHF),1 in whom several types of devices varying in location, pump size, mechanics, and design are ‘officially’ available in the market. On the contrary, children with ESHF refractory to conventional therapy have much fewer ‘official’ and well-accepted options which require a continuous hospitalization and hinder patients’ mobility.2-13
68 year old man from Bangalore, got a new life as he underwent heart and lungs transplant at Narayana Health City, Bangalore. The donor is a 24yr old male fr...
The risk of infection following heart transplantation is highest within the first year and represents the leading cause of early mortality. In this cohort of patients enrolled in the Outcomes AlloMap Registry (OAR), we sought to describe infection episodes (IEp) resulting in hospitalization, in early (
Pulmonary cuff dysfunction, either due to pulmonary vein obstruction, pulmonary vein stenosis, or pulmonary vein thrombosis is an uncommon, yet serious complication after lung transplantation. While there have been numerous reports of its occurrence, there is little consensus regarding the hemodynamic parameters associated with its presentation and diagnostic considerations. This systematic review summarizes the evidence surrounding pulmonary cuff dysfunction after lung transplantation surgery and empirically analyzes its implications.
Some literature exists potentially linking proliferation signal inhibitors (PSIs) to venous thromboembolism (VTE). We sought to determine the impact of PSI on development of VTE in heart transplant (HT) patients while controlling for other risk factors.
Vasoplegic syndrome (VS) is a type of vasodilatory shock defined by a constellation of a high cardiac output state, low systemic vascular resistance (SVR), low filling pressures, and low mean arterial pressure (MAP) despite high-dose vasoconstrictors. It is a well-known phenomenon following cardiopulmonary bypass (CPB), with a reported incidence of 8-10%,1 and is more common following left ventricular assist device (LVAD) placement (42%).2 VS is associated with significant morbidity and a mortality rate ranging from 16-27%.